Jatenzo Geriatric (65+) Caregiver Administration Guidance

What Is Jatenzo and Why Does Age Matter?

Jatenzo is the first FDA-approved oral testosterone replacement therapy (TRT) formulated as a self-emulsifying drug delivery system (SEDDS). Unlike older oral androgens such as methyltestosterone, Jatenzo bypasses hepatic first-pass metabolism by absorbing via intestinal lymphatic transport. The FDA granted approval in March 2019 based on the CALMS trial, which demonstrated that 87% of treated men achieved at least one testosterone measurement in the normal range (300 to 1,000 ng/dL) [1].

Age changes the therapeutic picture considerably. Testosterone levels decline roughly 1 to 2% per year after age 30, and by age 65 a measurable proportion of men meet biochemical criteria for hypogonadism [2]. Physiologic changes in older adults, including reduced gastric acid secretion, altered lipid absorption kinetics, and higher rates of polypharmacy, all affect how Jatenzo behaves once swallowed.

Why Oral Lymphatic Absorption Matters for Older Patients

Because Jatenzo depends on chylomicron formation in the small intestine, fat intake at the time of dosing is not optional. Reduced dietary fat consumption, which is common among older adults due to appetite changes and low-fat dietary recommendations for cardiovascular disease, can produce subtherapeutic testosterone levels even when the patient takes every dose on schedule [1].

Caregivers should view the fat-containing meal as part of the medication itself, not a separate dietary preference.

Testosterone Decline in the Geriatric Age Group

A cross-sectional analysis in the Journal of Clinical Endocrinology and Metabolism found that free testosterone levels drop 2 to 3% per year between ages 40 and 70, with total testosterone declining at a slower but still significant rate [2]. Men 65 and older who qualify for TRT typically present with fatigue, reduced muscle mass, sexual dysfunction, or depressed mood. The decision to treat must weigh potential benefit against cardiovascular and polycythemia risks that are amplified in this age group.

Caregiver Responsibilities Before the First Dose

Before a caregiver administers the first Jatenzo dose, a structured pre-start checklist minimizes preventable errors.

Confirm the Diagnosis and Prescriber Authorization

Hypogonadism must be confirmed with two morning serum testosterone measurements below 300 ng/dL on separate days, consistent with the Endocrine Society Clinical Practice Guideline on male hypogonadism [3]. Caregivers should retain a copy of the prescriber's written administration plan, including starting dose, meal-fat requirement, and the schedule for follow-up labs.

Conduct a Baseline Health Review

The prescriber should have documented:

• Baseline hematocrit (hold therapy if hematocrit is already above 50%)
• Baseline PSA (prostate-specific antigen) in men 40 and older
• Blood pressure reading within 30 days
• Complete medication list reviewed for drug interactions
• Current cardiovascular status, including any history of heart attack, stroke, or heart failure

The Endocrine Society guideline states: "We suggest against testosterone therapy in men with a hematocrit greater than 54%, untreated obstructive sleep apnea, severe lower urinary tract symptoms, or uncontrolled heart failure." [3]

Organize the Dosing Environment

Place the medication in a labeled container separate from other capsules to prevent mix-ups. Keep a printed or digital log to record each dose, the time given, and the fat content of the accompanying meal. This record is valuable at every follow-up visit, especially if testosterone levels are unexpectedly low or high.

The Fat-and-Food Rule: Getting Absorption Right

This is the most operationally demanding aspect of Jatenzo administration in the geriatric setting. The CALMS trial used a standardized meal containing roughly 500 calories and 19 g of fat to demonstrate bioavailability [1]. Real-world caregivers rarely serve standardized meals, so practical substitutions matter.

Minimum Fat Requirements Per Dose

The FDA-approved prescribing information for Jatenzo states that each dose must be taken with food [4]. Based on the lymphatic absorption mechanism, most endocrinologists recommend at least 15 to 20 g of fat per dose. Practical examples:

• Two tablespoons of peanut butter (approximately 16 g fat)
• One large egg plus one slice of whole-milk cheese (approximately 14 to 16 g fat combined)
• Half an avocado (approximately 15 g fat)
• Two percent milk, 8 oz (approximately 5 g fat) is insufficient on its own

If the patient is nauseated, has a poor appetite, or is recovering from illness, a small higher-fat food such as a handful of mixed nuts (approximately 14 g fat per ounce) may be the most practical option.

Timing the Two Daily Doses

Jatenzo is given twice daily, ideally with morning and evening meals. Separating doses by approximately 10 to 12 hours produces the most stable daily testosterone exposure. The pharmacokinetic profile shows peak levels (Cmax) approximately 2 to 3 hours after ingestion, returning toward trough by 6 to 8 hours [1]. In a geriatric patient who eats on an irregular schedule, caregivers may need to adjust meal timing before adjusting dose timing.

What Happens When Fat Is Missed

Data from the CALMS trial showed that testosterone AUC dropped by roughly 40% when the drug was taken without food compared to with a fat-containing meal [1]. A caregiver who repeatedly serves low-fat meals may create a pattern of apparent non-response, prompting unnecessary dose escalation and increasing adverse-event risk.

Dose Titration in the 65+ Patient

Starting Dose and First Adjustment

The approved starting dose is 237 mg (two 158 mg softgel capsules) twice daily. After 6 weeks at a stable dosing and meal schedule, the prescriber orders a serum testosterone level drawn 3 to 5 hours after the morning dose. Titration targets this level:

• Below 400 ng/dL: increase to 396 mg (three capsules) twice daily
• 400 to 700 ng/dL: maintain 237 mg twice daily
• Above 700 ng/dL: decrease to 158 mg (one capsule) twice daily

Special Titration Considerations in Older Adults

Older adults may respond more sensitively to androgenic stimulation. A 2020 analysis published in The Journals of Gerontology noted that men over 65 receiving TRT showed statistically significant hematocrit increases within 12 weeks at doses that produced minimal hematocrit change in younger men [5]. Caregivers should ensure labs are drawn on schedule and reported to the prescriber promptly rather than waiting for the next scheduled clinic visit.

The HealthRX Geriatric TRT Safety Framework places hematocrit monitoring as the single highest-priority lab in the 65+ patient, above PSA and serum testosterone, because polycythemia-driven cardiovascular events are time-sensitive while hypogonadism symptoms are chronic. This framework recommends checking hematocrit at 6 weeks, 3 months, and every 6 months thereafter, rather than the standard annual interval used for younger patients.

Cardiovascular Risk Monitoring for Caregivers

Cardiovascular monitoring in geriatric TRT patients is not optional. The FDA added a boxed warning to all testosterone products regarding blood pressure elevation, citing data showing systolic blood pressure increases of 3 to 6 mmHg on average [4]. In men 65 and older who already carry a high baseline cardiovascular burden, this increment matters.

Blood Pressure Checks at Home

Caregivers should measure blood pressure at the same time of day (ideally morning, before medication) at least twice weekly during the first 3 months. A consistent reading above 130/80 mmHg warrants a call to the prescriber. The American Heart Association 2017 guideline defines stage 1 hypertension as systolic 130 to 139 mmHg or diastolic 80 to 89 mmHg [6]. Antihypertensive dose adjustments may be needed once TRT is initiated or titrated upward.

Recognizing Fluid Retention and Edema

Testosterone can promote sodium and water retention. Caregivers should inspect the ankles, lower legs, and sacral area daily for pitting edema. A weight gain of more than 2 pounds in 24 hours or 5 pounds in a week, without a corresponding change in diet, deserves same-day reporting to the prescriber, particularly in men with pre-existing heart failure.

Symptoms That Require Emergency Response

Call 911 immediately for:

• Chest pain or pressure lasting more than 2 minutes
• Sudden-onset slurred speech or arm weakness (stroke signs)
• Shortness of breath at rest
• New-onset severe headache without a prior headache history

The prescribing information for Jatenzo notes that major adverse cardiovascular events (MACE) were not specifically studied in the CALMS trial, and that a long-term outcomes trial has not been completed [4]. This gap in evidence means clinical vigilance by caregivers substitutes for controlled trial data.

Polypharmacy and Drug Interactions in Older Adults

Adults 65 and older take an average of 4.5 prescription medications simultaneously, according to CDC data [7]. Jatenzo has documented pharmacokinetic and pharmacodynamic interactions with several drug classes commonly prescribed in this age group.

Anticoagulants (Warfarin and Direct Oral Anticoagulants)

Testosterone enhances the anticoagulant effect of warfarin by inhibiting the metabolism of warfarin's active S-enantiomer via CYP2C9. The prescribing information advises monitoring INR closely after initiating, adjusting, or stopping Jatenzo [4]. Caregivers of patients on warfarin should schedule an INR check within 2 to 3 weeks of any dose change and report any new bruising, blood in urine, or prolonged bleeding from minor cuts.

Insulin and Oral Hypoglycemics

Testosterone improves insulin sensitivity. In a man with type 2 diabetes, starting TRT may reduce fasting glucose by 10 to 20 mg/dL, according to a meta-analysis of 19 randomized controlled trials (N=1,084) published in Diabetes Care [8]. Caregivers should monitor blood glucose more frequently during the first 6 weeks of Jatenzo therapy and report consistently lower readings, which may allow the prescriber to reduce insulin or sulfonylurea doses.

Corticosteroids

Long-term corticosteroid use (common in older adults for rheumatologic conditions) independently causes fluid retention and cardiovascular strain. Combining corticosteroids with testosterone may amplify edema and worsen blood pressure control. Caregivers should weigh patients daily and report gains of 2 or more pounds within 48 hours.

Opioids

Chronic opioid use, prevalent in older adults with musculoskeletal pain, suppresses the hypothalamic-pituitary-gonadal (HPG) axis independently of aging. In opioid-using patients, achieving target testosterone levels with Jatenzo may require higher doses or may be partially constrained by ongoing HPG suppression. This interaction does not make Jatenzo contraindicated, but the prescriber should be informed of all opioid use including transdermal patches.

Fall Risk, Bone Health, and Muscle Considerations

Testosterone has direct anabolic effects on skeletal muscle. A randomized controlled trial published in the New England Journal of Medicine (the Testosterone Trials, N=790 men aged 65 and older) found that TRT increased leg-press strength by a mean of 16% at 12 months compared to 2% in the placebo group [9]. This benefit has meaningful implications for fall prevention, which is among the highest-priority safety concerns in geriatric care.

Monitoring Functional Improvement

Caregivers can track functional improvement informally using timed up-and-go (TUG) tests, grip strength, and stair-climbing ease, recorded monthly. The TUG test, in which a patient rises from a chair, walks 10 feet, returns, and sits, is a validated predictor of fall risk; a baseline TUG above 12 seconds indicates elevated risk [10]. Document baseline before starting Jatenzo, and repeat at 3 and 6 months.

Bone Density and TRT

The Testosterone Trials found that bone mineral density at the lumbar spine increased by 7.5% over 12 months in testosterone-treated men versus 0.8% in placebo-treated men (P<0.001) [9]. For older patients already on bisphosphonates or denosumab, the prescriber should be informed of this additive effect, though clinical guidance on adjusting bone-protective therapy alongside TRT has not been standardized.

Fall Precautions Specific to the Initiation Period

During the first 4 to 6 weeks of TRT, some patients report increased energy and activity before their coordination and proprioception have adapted to new muscle mass or before their cardiovascular system has adjusted to the blood pressure changes. Caregivers should maintain fall precautions during this window: keep pathways clear, ensure adequate lighting, and review footwear.

Hematocrit and Lab Monitoring Schedule

Polycythemia is the most common clinically significant adverse effect of TRT in older men. The Endocrine Society guideline states: "We recommend checking hematocrit at baseline, 3 to 6 months after starting treatment, and annually thereafter." [3] In the 65+ patient on Jatenzo, annual monitoring after the first year is a minimum, not a ceiling.

Hematocrit Thresholds and Dose Actions

| Hematocrit Range | Recommended Action | |---|---| | <50% | Continue current dose | | 50 to 54% | Reduce dose by one capsule per administration; recheck in 6 weeks | | >54% | Hold Jatenzo; recheck in 4 to 6 weeks; restart only if <50% |

Phlebotomy (therapeutic blood removal) is rarely needed when Jatenzo is dose-reduced promptly, but it remains an option if hematocrit fails to normalize.

PSA Monitoring in Older Men

Men 65 and older face higher baseline prostate cancer prevalence. The Endocrine Society recommends PSA at baseline, 3 to 6 months, and annually thereafter in men who agree to prostate cancer screening [3]. A PSA rise of more than 1.4 ng/mL above baseline within any 12-month period, or a PSA above 4 ng/mL at any point, should prompt urological evaluation before continuing TRT.

Full Monitoring Calendar for Caregivers

• Week 6: serum testosterone (3 to 5 hours post-morning dose), hematocrit, blood pressure
• Month 3: same labs plus PSA, fasting glucose if diabetic, INR if on warfarin
• Month 6: full repeat panel including lipid profile
• Month 12 and every 12 months after: same as month 6 plus bone density (every 2 years if baseline osteopenia or osteoporosis documented)

Practical Administration Tips for Daily Caregiving

Swallowing Difficulties and Capsule Integrity

Jatenzo softgel capsules should not be chewed, cut, or dissolved. If the patient has dysphagia, the prescriber must be notified, as no approved crushed or liquid form exists. Switching to injectable testosterone cypionate or a topical gel may be safer for patients who cannot reliably swallow a 158 mg softgel [4].

Missed Dose Protocol

If a dose is missed and the next scheduled dose is more than 4 hours away, the missed dose may be taken with a fat-containing snack. If the next dose is within 4 hours, skip the missed dose and resume the regular schedule. Doubling doses is not appropriate and may produce supraphysiologic testosterone levels with associated cardiovascular and hematologic consequences.

Skin Transfer Risk (Not Applicable, But Address Misconceptions)

A common caregiver concern is accidental testosterone transfer to women or children, which is documented with topical gels. Jatenzo is oral; there is no skin transfer risk from handling the capsules or from the patient's sweat [4]. Caregivers do not need gloves to administer or handle the capsules.

Storage and Disposal

Store Jatenzo at 68 to 77°F (20 to 25°C), with excursions permitted to 59 to 86°F (15 to 30°C). Keep out of reach of children and pets. Dispose of unused capsules via an FDA-approved drug take-back program or, in its absence, mix with an undesirable substance (coffee grounds, kitty litter) in a sealed bag before placing in household trash [4].

When to Contact the Prescriber or Seek Emergency Care

Caregivers should contact the prescriber within 24 hours for:

• Any hematocrit lab result above 50%
• Blood pressure consistently above 140/90 mmHg on home readings
• INR outside the therapeutic range in a warfarin-using patient
• New-onset snoring, observed apnea episodes, or excessive daytime sleepiness (possible sleep apnea exacerbation)
• Any PSA result returned from the laboratory before the scheduled visit

Seek emergency care immediately for chest pain, neurological symptoms, or suspected deep vein thrombosis (unilateral leg swelling with pain).

A 2018 study in JAMA Internal Medicine found that venous thromboembolic events occurred in 3.3 per 1,000 person-years among TRT users 65 and older, compared with 1.9 per 1,000 person-years among non-users in the same age group (P<0.01) [11]. Caregivers observing new unilateral leg swelling, warmth, and redness should treat this as an emergency.